Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Astria Therapeutics, Inc. - Common Stock (NQ:ATXS)

12.86 +0.04 (+0.31%)
Streaming Delayed Price Updated: 11:21 AM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astria Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Preview For Astria Therapeutics ↗
 
Via Benzinga
News headline image
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q1 2024 ↗
ATXS stock results show that Astria Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and... 
Via Benzinga
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q4 2023 ↗
ATXS stock results show that Astria Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
$5.6M Bet On This Real Estate Stock? Check Out These 3 Stocks Insiders Are Buying ↗
Although U.S. stocks closed mixed on Friday, there were a few notable insider trades. 
Via Benzinga
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming 6th Annual Evercore ISI HealthCONx Conference
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 13, 2023 ↗
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.